Ranolazine: Drug Profile and Safety Information

What is Ranolazine?

Ranolazine is an antianginal medication that belongs to a unique class of drugs known as selective inhibitors of the late sodium current in heart muscle cells. It is primarily prescribed to treat chronic angina (chest pain) in patients who have not responded adequately to other antianginal therapies. Unlike traditional heart medications, ranolazine works through a novel mechanism that helps improve blood flow to the heart muscle without significantly affecting heart rate or blood pressure.

Uses

Ranolazine is approved and used for several cardiovascular conditions:

• Chronic angina: Primary indication for patients with stable coronary artery disease who continue to experience chest pain despite optimal treatment with other medications
• Combination therapy: Used alongside beta-blockers, calcium channel blockers, or nitrates when single-agent therapy is insufficient
• Microvascular angina: May help patients with chest pain due to small vessel coronary disease
• Diabetic patients with angina: Particularly beneficial for diabetic patients who often have more complex coronary disease
• Refractory angina: Reserved for patients who cannot undergo revascularization procedures or continue to have symptoms after such procedures

How it works

Ranolazine works by selectively blocking the late sodium current in cardiac muscle cells, which reduces calcium overload within heart muscle fibers. This mechanism helps the heart muscle relax more effectively during the filling phase of the cardiac cycle, improving blood flow through compressed coronary vessels. Unlike other antianginal drugs, ranolazine achieves these benefits without significantly reducing heart rate, blood pressure, or the heart’s pumping ability.

Side effects

Common side effects include:

Submit Your Paper

• Dizziness or lightheadedness
• Nausea and stomach upset
• Constipation
• Headache
• Weakness or fatigue
• Dry mouth
• Sweating
• Ringing in the ears (tinnitus)

Serious side effects requiring immediate medical attention:

• Irregular heartbeat or palpitations
• Severe dizziness or fainting
• Kidney problems (decreased urination, swelling)
• Severe allergic reactions (rash, difficulty breathing, swelling of face or throat)
• Signs of liver problems (yellowing of skin or eyes, severe abdominal pain)

Warnings and precautions

• QT prolongation: Ranolazine can cause changes in heart rhythm, particularly in patients with existing heart rhythm disorders or those taking other QT-prolonging medications
• Kidney function: Dosage adjustments are necessary for patients with moderate to severe kidney impairment, and the drug should be used cautiously in elderly patients who may have reduced kidney function
• Liver disease: Patients with severe liver impairment should avoid ranolazine, as the drug is extensively metabolized by the liver
• Pregnancy and nursing: Ranolazine is classified as pregnancy category C, meaning it should only be used during pregnancy if potential benefits justify the risks to the fetus
• Emergency situations: Ranolazine is not intended for acute angina episodes and should not be used to treat heart attacks or unstable angina

Interactions

Ranolazine has several important drug interactions due to its metabolism through liver enzymes:

• Strong CYP3A inhibitors (ketoconazole, clarithromycin): Can significantly increase ranolazine levels, requiring dosage adjustments or avoidance
• CYP3A inducers (rifampin, phenytoin): May reduce ranolazine effectiveness by increasing its breakdown
• Digoxin: Ranolazine can increase digoxin levels, requiring careful monitoring and possible dose reduction
• Simvastatin: Concurrent use may increase simvastatin levels, potentially leading to muscle toxicity
• QT-prolonging medications (quinidine, sotalol): Combined use increases risk of dangerous heart rhythm abnormalities
• Metformin: Ranolazine may increase metformin levels, requiring blood sugar monitoring
• Grapefruit juice: Should be avoided as it can increase ranolazine concentrations
• St. John’s wort: This herbal supplement may reduce ranolazine effectiveness

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose of ranolazine for adults is 500 mg taken twice daily with or without food. Based on clinical response and tolerability, the dose may be increased to 1000 mg twice daily after 2-4 weeks. The maximum recommended dose is 1000 mg twice daily. Patients with moderate kidney impairment may require lower doses, and those with severe kidney or liver impairment should generally avoid this medication. Dosage should always be determined and monitored by a healthcare provider, who will consider individual patient factors and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).